Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Post by davgroon Aug 30, 2023 3:48pm
298 Views
Post# 35612634

"Finally Some Good News" On Cannabis, says Wedbush

"Finally Some Good News" On Cannabis, says Wedbush 2023-08-30 03:23:23 PM ET (MT Newswires)

03:23 PM EDT, 08/30/2023 (MT Newswires) -- Today, in what was "very encouraging news" for the sector, the U.S. Dep't of Health and Human Services (HHS) officially recommended to the U.S. Drug Enforcement Administration (DEA) that cannabis be moved from its current Schedule I to Schedule III of the Controlled Substances Act, Wedbush said Wednesday. 
 
Following its scientific review of cannabis, the HHS now believes cannabis should be moved to a lower schedule (Schedule III) within the Controlled Substances Act, given it is currently marked as a Schedule I drug. Wedbush noted while the recommendation is not binding, and the decision will ultimately depend on the DEA's ruling, the HHS' analysis will likely influence the DEA's decision.
 
Wedbush said: "While cannabis would still remain federally illegal as a Schedule III drug, rescheduling it to a lower Schedule would have significant, industry wide implications, chief among which would be the relief from punitive 280E tax provision, arguably the most penal of all regulatory hurdles facing multi-state operators (MSOs), which effectively requires operators to pay effective tax rates between 60-90%. To be sure, rescheduling cannabis from Schedule I to Schedule III would be materially beneficial from a profitability and cash flow perspective, at a time when all MSOs are focused on cash preservation."
 
In its take, Wedbush said it views today's news as "very encouraging" for an industry that has seen no meaningful regulatory progress over the past few years, and particularly since the failure of lawmakers to pass SAFE during last year's lame duck session. "While the recommendation has yet to be confirmed by the DEA, we view this as a positive development, which materially increase the odds of a rescheduling to Schedule III, which as mentioned would be a boon for the industry," it added.
<< Previous
Bullboard Posts
Next >>